- Home
- MVSTW vs MIST Comparison
MVSTW vs MIST Comparison
Compare MVSTW & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVSTW | MIST |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Canada |
| Employees | 1921 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 176.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MVSTW | MIST |
|---|---|---|
| Price | $0.01 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 112.5K | ★ 2.1M |
| Earning Date | 03-14-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $370,989,000.00 | N/A |
| Revenue This Year | N/A | $1,653.36 |
| Revenue Next Year | N/A | $12.32 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.03 | N/A |
| 52 Week Low | $0.01 | $0.63 |
| 52 Week High | $0.65 | $3.06 |
Technical Indicators
Market Signals| Indicator | MVSTW | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 46.10 |
| Support Level | N/A | N/A |
| Resistance Level | $0.07 | $2.01 |
| Average True Range (ATR) | 0.01 | 0.13 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 5.75 | 48.10 |
Price Performance
Historical ComparisonAbout MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).